Takeda Pharmaceutical Company Limited

First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

Global partner outside Greater China

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

Updated Jun 4

First TYK2 inhibitor reaches FDA decision for psoriatic arthritis

New Capabilities

Developing competing TYK2 inhibitor zasocitinib (TAK-279) in Phase 3

For most of the past decade, people with psoriatic arthritis who wanted a pill had one real choice: Janus kinase (JAK) inhibitors. The FDA slapped those drugs with its strongest safety warning in 2021, after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death.

Updated May 30

Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance

New Capabilities

Sponsor and owner of zasocitinib; preparing FDA filings and broader immunology expansion

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated May 15

Takeda Pharmaceutical Company Limited

Stories

First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

First TYK2 inhibitor reaches FDA decision for psoriatic arthritis

Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance